Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manica Balasegaram

Showing results (1-10 of 75) with videos related to

Pageof 8
Sort By:
The Lancet. Global Health|April 15, 2022
Antimicrobial subscription and pooled procurementManica Balasegaram
ACS Infectious Diseases|March 8, 2021
Learning from COVID-19 to Tackle Antibiotic ResistanceManica Balasegaram
Lancet (London, England)|September 12, 2014
Is tiered pricing the way for vaccines?Manica Balasegaram
Nature|March 28, 2014
WHO: Steering plans for neglected diseasesBernard Pécoul, Manica Balasegaram
The Lancet. Infectious Diseases|August 29, 2014
Empiric tuberculosis treatment in retreatment patients in high HIV/tuberculosis-burden settingsManica Balasegaram, Grania Brigden
Nature Reviews. Microbiology|September 13, 2024
Achieving sustainable access to antibiotics is more than just a last mile challengeManica Balasegaram, Viviana Muñoz Tellez
ACS Infectious Diseases|May 15, 2020
The Global Antibiotic Research and Development Partnership (GARDP) Not-for-Profit Model of Antibiotic DevelopmentManica Balasegaram, Laura J V Piddock
The Lancet. Global Health|August 9, 2014
Different liposomal amphotericin B formulations for visceral leishmaniasisThomas P C Dorlo, Manica Balasegaram
The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics|August 6, 2015
The Global Innovation Model for Antibiotics Needs ReinventionManica Balasegaram, Charles Clift, John-Arne Røttingen
Lancet (London, England)|September 23, 2024
The time to address the antibiotic pipeline and access crisis is nowManica Balasegaram, Kevin Outterson, John-Arne Røttingen
Pageof 8

Showing results (1-10 of 75) with videos related to

Sort By:
Pageof 8
The Lancet. Global Health|April 15, 2022
Antimicrobial subscription and pooled procurementManica Balasegaram
ACS Infectious Diseases|March 8, 2021
Learning from COVID-19 to Tackle Antibiotic ResistanceManica Balasegaram
Lancet (London, England)|September 12, 2014
Is tiered pricing the way for vaccines?Manica Balasegaram
Nature|March 28, 2014
WHO: Steering plans for neglected diseasesBernard Pécoul, Manica Balasegaram
The Lancet. Infectious Diseases|August 29, 2014
Empiric tuberculosis treatment in retreatment patients in high HIV/tuberculosis-burden settingsManica Balasegaram, Grania Brigden
Nature Reviews. Microbiology|September 13, 2024
Achieving sustainable access to antibiotics is more than just a last mile challengeManica Balasegaram, Viviana Muñoz Tellez
ACS Infectious Diseases|May 15, 2020
The Global Antibiotic Research and Development Partnership (GARDP) Not-for-Profit Model of Antibiotic DevelopmentManica Balasegaram, Laura J V Piddock
The Lancet. Global Health|August 9, 2014
Different liposomal amphotericin B formulations for visceral leishmaniasisThomas P C Dorlo, Manica Balasegaram
The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics|August 6, 2015
The Global Innovation Model for Antibiotics Needs ReinventionManica Balasegaram, Charles Clift, John-Arne Røttingen
Lancet (London, England)|September 23, 2024
The time to address the antibiotic pipeline and access crisis is nowManica Balasegaram, Kevin Outterson, John-Arne Røttingen
Pageof 8